Bria-IMT plus a checkpoint inhibitor showed a 52% one-year survival rate in metastatic breast cancer patients, surpassing standard therapy outcomes. The treatment was well-tolerated, with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results